Lipoxygenase metabolism: roles in tumor progression and survival

被引:234
作者
Pidgeon, Graham P. [1 ]
Lysaght, Joanne
Krishnamoorthy, Sriram
Reynolds, John V.
O'Byrne, Ken
Nie, Daotai
Honn, Kenneth V.
机构
[1] St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Dept Clin Surg, Dublin 8, Ireland
[2] St James Hosp, Trinity Coll, Dept Clin Surg, Dublin, Ireland
[3] St James Hosp, Trinity Coll, Dept Haematol, Dublin, Ireland
[4] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48202 USA
[5] St James Hosp, Trinity Coll, Dept Clin Med, Dublin, Ireland
[6] So Illinois Univ, Sch Med, Inst Canc, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA
关键词
lipoxygenase; tumor survival; apoptosis; angiogenesis; immune suppression;
D O I
10.1007/s10555-007-9098-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The metabolism of arachidonic acid through lipoxygenase pathways leads to the generation of various biologically active eicosanoids. The expression of these enzymes vary throughout the progression of various cancers, and thereby they have been shown to regulate aspects of tumor development. Substantial evidence supports a functional role for lipoxygenase-catalyzed arachidonic and linoleic acid metabolism in cancer development. Pharmacologic and natural inhibitors of lipoxygenases have been shown to suppress carcinogenesis and tumor growth in a number of experimental models. Signaling of hydro[peroxy]fatty acids following arachidonic or linoleic acid metabolism potentially effect diverse biological phenomenon regulating processes such as cell growth, cell survival, angiogenesis, cell invasion, metastatic potential and immunomodulation. However, the effects of distinct LOX isoforms differ considerably with respect to their effects on both the individual mechanisms described and the tumor being examined. 5-LOX and platelet type 12-LOX are generally considered pro-carcinogenic, with the role of 15-LOX-1 remaining controversial, while 15-LOX-2 suppresses carcinogenesis. In this review, we focus on the molecular mechanisms regulated by LOX metabolism in some of the major cancers. We discuss the effects of LOXs on tumor cell proliferation, their roles in cell cycle control and cell death induction, effects on angiogenesis, migration and the immune response, as well as the signal transduction pathways involved in these processes. Understanding the molecular mechanisms underlying the anti-tumor effect of specific, or general, LOX inhibitors may lead to the design of biologically and pharmacologically targeted therapeutic strategies inhibiting LOX isoforms and/or their biologically active metabolites, that may ultimately prove useful in the treatment of cancer, either alone or in combination with conventional therapies.
引用
收藏
页码:503 / 524
页数:22
相关论文
共 159 条
  • [1] Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
  • [2] Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity
    Aliberti, J
    Hieny, S
    Sousa, CRE
    Serhan, CN
    Sher, A
    [J]. NATURE IMMUNOLOGY, 2002, 3 (01) : 76 - 82
  • [3] Anderson KM, 1998, PROSTATE, V37, P161, DOI 10.1002/(SICI)1097-0045(19981101)37:3<161::AID-PROS5>3.0.CO
  • [4] 2-D
  • [5] PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways
    Appel, S
    Mirakaj, V
    Bringmann, A
    Weck, MM
    Grünebach, F
    Brossart, P
    [J]. BLOOD, 2005, 106 (12) : 3888 - 3894
  • [6] Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition
    Avis, I
    Martínez, A
    Tauler, J
    Zudaire, E
    Mayburd, A
    Abu-Ghazaleh, R
    Ondrey, F
    Mulshine, JL
    [J]. CANCER RESEARCH, 2005, 65 (10) : 4181 - 4190
  • [7] Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells
    Baratelli, F
    Lin, Y
    Zhu, L
    Yang, SC
    Heuzé-Vourc'h, N
    Zeng, G
    Reckamp, K
    Dohadwala, M
    Sharma, S
    Dubinett, SM
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (03) : 1483 - 1490
  • [8] Assessing 12(S)-lipoxygenase inhibitory activity using colorectal cancer cells overexpressing the enzyme
    Bednar, Wolfgang
    Holzmann, Klaus
    Marian, Brigitte
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2007, 45 (03) : 508 - 514
  • [9] Tumorigenesis and the angiogenic switch
    Bergers, G
    Benjamin, LE
    [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 401 - 410
  • [10] Bissell MJ, 1999, CANCER RES, V59, p1757S